Navigation Links
Avant’s Typhoid Fever Vaccine Demonstrates Excellent Clinical,Potential

resented today at a vaccines meeting in Baltimore, MD entitled “Progress and Opportunities in the Prevention of Enteric Disease” by the Principal Investigator, Dr. Cohen. It is expected that detailed results of the study will be published in a scientific journal.

About AVANT Immunotherapeutics, Inc.
AVANT Immunotherapeutics, Inc. discovers and develops innovative vaccines and therapeutics that harness the human immune system to prevent and treat disease. AVANT has three products on the market and four of AVANT’s products are in clinical development. AVANT’s pipeline includes products for travelers’ vaccines and global health needs based on AVANT’s oral, rapid-protecting, single-dose and temperature-stable vaccine technology.

Additional information on AVANT Immunotherapeutics, Inc. can be obtained through its site on the World Wide Web: http://www.avantimmune.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that are subject to a variety of risks and uncertainties and reflect AVANT’s current views with respect to future events and financial performance. There are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by AVANT. These factors include, but are not limited to: (1) the integration of multiple technologies and programs; (2) the ability to adapt AVANT’s vectoring systems to develop new, safe and effective orally administered vaccines against anthrax and plague or other any other microbes used as bioweapons and other disease causing agents; (3) the ability to successfully complete product research and further development, including animal, pre-clinical and clinical studies, and commercialization of CholeraGarde® (Peru-15), Ty8
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Avants Typhoid Fever Vaccine Demonstrates Excellent Clinical Potential
2. SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193
3. Placebo-controlled Phase IIa Study with the Immunotherapeutic CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in Hay Fever Patients
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
6. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
7. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
8. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
9. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
10. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
11. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
Post Your Comments:
(Date:9/1/2015)... The global Bioinformatics ... sectors, products & services and application. And the rising ... increasing demand of advanced drugs for the diagnosis ... growth for bioinformatics market. The implementation of information ... as bioinformatics. Decreasing cost of DNA sequencing, continuous ...
(Date:9/1/2015)... Research and Markets ( http://www.researchandmarkets.com/research/r8v22b/regulatory ) has announced the ... (London, UK - September 24-25, 2015)" conference to ... provides an introduction to Pharmaceutical Regulatory Affairs and the ... for those working in a support staff role. ... regulatory procedures required to register products in ...
(Date:9/1/2015)... , September 1, 2015 - ... GARFIELD-AF R egistry data presented at ... on the evolution of manag ... -   The first-ever two-year outcomes from ... ESC Congress 2015 expose that all-cause death was the most frequent major event ...
Breaking Medicine Technology:Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4Regulatory Affairs for Support Staff Seminar (London, UK - September 24-25, 2015) 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 3Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 4Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 5Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 6Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 7Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 8Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 9
(Date:9/1/2015)... Jersey (PRWEB) , ... September 01, 2015 , ... Horizon ... of the 50 Best Companies for Latinas in the LATINA Style 50 Report that ... States. , For 2015, Horizon BCBSNJ climbs from number 24 to ...
(Date:9/1/2015)... ... 01, 2015 , ... Splashtop Inc. , the worldwide ... , a solution optimized for MSPs and IT professionals looking for a cost ... inadequate customer services of existing remote support solution, many MSPs and ITs have ...
(Date:9/1/2015)... Florida (PRWEB) , ... September ... ... of Professional Background Screeners (NAPBS®) has announced that Edge Information Management ... conducted by the Background Screening Credentialing Council (BSCC). , “Achieving and ...
(Date:9/1/2015)... MA (PRWEB) , ... September 01, 2015 , ... ... today announced the release of version 5.2 of the FirstSpirit Content Management System ... Cloud initiative. With the new version of FirstSpirit, companies will be well on ...
(Date:9/1/2015)... Washington, D.C. (PRWEB) , ... September 01, 2015 , ... ... to better cross cultural relations through food and dining. , Recently named “the ... Riolo and Luigi Diotaiuti are known for telling the whole story behind food and ...
Breaking Medicine News(10 mins):Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 2Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 2Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 4Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 4
... painful condition that has become more common in aged people. ... joint // replacement as a treatment for the condition. A ... & Research examined whether asking patients to follow an exercise ... restoring function after surgery. ,Led by Daniel S. ...
... Virginia (UVa) and Reckitt-Benckiser (LON: RB) have found that ... // to the amount of viral contamination left behind ... the annual Interscience Conference on Antimicrobial Agents and Chemotherapy ... cold virus easily transferred the virus to 35 percent ...
... Sweden have developed a new drug that can combat ... almost 2 million lives annually. Some of the symptoms ... ,The diseases are caused when the malaria ... accumulate in large amounts, blocking the flow of blood ...
... of at least 15 people who had undergone cataract operation ... after they suffered // from severe post-operative complications, an official ... surgery on a few senior citizens at the neighbouring Deogarh ... under the aegis of National Blindness Control Programme. ...
... report has found that prices of 200 brand name drugs which ... the 12 month period ending // mid June 2006, against an ... reported in their Rx Watchdog Report released on Tuesday. It is ... remain the same. ,Heading the list of drugs with ...
... men with prostate cancer treated with high-dose, intensity modulated ... patients remain alive with no evidence of disease after ... ,The 561 prostate cancer patients treated with IMRT at ... groups. After an average of eight years, 89 percent ...
Cached Medicine News:Health News:Does Exercise Before Hip Replacement Help? 2Health News:Common Cold All Too Easy To Catch 2Health News:Common Cold All Too Easy To Catch 3Health News:Common Cold All Too Easy To Catch 4Health News:Brand Name Drug Prices Zoom 2Health News:Long-Term Outcomes for Prostate Cancer Show IMRT Curative 2
Used to negotiate tortuous vessels....
BiodivYsio stent with biocompatible coating (phosphorylcholine)...
... The CYPHER Sirolimus-eluting Coronary Stent ... drug, called "sirolimus", a controlled-release ... delivery platform. Upon placement, sirolimus ... and impedes the process of ...
PT wires combine the enhanced durability of a linear elastic nitinol distal core and a highly resilient polymer tip. This provides excellent access in difficult cases involving severe tortuosity, tig...
Medicine Products: